CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Ryan Cross

Senior Science Correspondent

The promise of a one-and-done CRISPR infusion is beginning to look more real than ever.
On Thursday, Intellia Therapeutics announced that an experimental gene editing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Senior Science Correspondent

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study